Be the first to hear the latest HemOnc news and best practice from the world’s leading experts 👨‍🔬👩‍🔬 Stay tuned for videos, podcasts and articles published live from the latest virtual meetings! #HemOnc #Leusm #Lymsm #MMSM #MDSsm #MPNsm #BMTsm #CTSM #ImmunoOnc #BleedingDisorders

#MCCRWorkshop The Workshop is organised by EORTC ESMO - Eur. Oncology and AACR and has provided training to over 1800 investigators from all over the world since its’ inception in 1999. Apply NOW eortc.org/mccr #clinicaltrialdesign #clinicaltrials

Register now for VJ Oncology's post-ASCO VJSessions! Join us for a series of roundtable discussions with #oncology experts to review key highlights from #ASCO21 Click for more details 👇👇 GI: tinyurl.com/GI-session GU: tinyurl.com/gu-sessions Breast: tinyurl.com/breast-sessions

Enjoying the gastrointestinal cancer oral abstract session? 🤔 Register to our upcoming #VJSession, a roundtable discussion on the latest learnings in GI from #ASCO21 Register here ➡️tinyurl.com/the-gi-session ASCO OncoAlert #GIsm

🕙 Just 10 days to go until ESMO #WorldGI2021 starts and VJ Oncology are excited to report on the biggest news from the meeting Check out 👉 vjoncology.com 👈 for exclusive interviews, podcasts and more! ESMO - Eur. Oncology #CRCSM #HPBCsm #STCsm #ESOCsm #GICancer #ayacsm

Happy Fourth of July! Wishing you a safe and enjoyable holiday with friends and family. #July4th

Excited to be on our first call for the new ⁦ASCO⁩ monthly plenary series. See attached for dates of presentations and submissions. Exciting to get data out there within 5-6 weeks of submission. Monthly Plenary Series | ASCO asco.org/meetings-educa…

We are excited to share our latest cancer research insights through more than 140 abstracts and presentations at #ASCO22. Read about where you can find our scientific experts at this year’s annual meeting. sarahcannon.com/about/newsroom…

Ellipses Announces FDA Clearance of IND Application for EP0031 for Patients With ... - goo.gl/alerts/1QWMK #GoogleAlerts #RETcancer #Lungcancer #researchmaters

Ellipses Begins Phase I/II Trial of EP0031 in RET-Altered Tumors precisiononcologynews.com/cancer/ellipse…

The burden of bureaucracy in clinical research has increased for investigators & clinical research teams. ESMO proposes a framework to streamline clinical research & reduce the bureaucracy in clinical trials, promoting better care for cancer patients. 🔗annalsofoncology.org/article/S0923-…

Next generation selective RET inhibitor EP0031/A400 - convincing and solid data presented by Prof Zhou.

🎯 🧬 KL590586 (A400/EP0031) A next-generation selective RET inhibitor in patients with RET-altered solid tumors. ORR 60% and DCR 95% for all tumor types and doses. 🫁 In NSCLC: ORR 81% in 1L and 70% in 2L. Also 🧠 activity proven #ASCO23 #LCSM

Thrilled to be a speaker at the Economist Impact World Cancer Series Europe 2023 on Sept 20th - 21st. Join me and the panel as we discuss Women's Cancer. Together, we can make a meaningful impact! #EconWorldCancerSeries #CancerResearch #WomensHealth

#Targets23 Great work from Drs. Arianna Marinello, MD Mihaela Aldea and others on characterizing outcomes in #RET NSCLC post progression on selective inhibitors: patterns of progression, response to subsequent lines of therapy.

I was happy to see Dr. @ElenaGarralda again - presenting work on EP0031, a next generation #RET inhibitor with impressive efficacy after selective RET inhibitors and CNS efficacy. #Targets23

📄 Access the poster presentation for Asset EP0031, shared by Tobias Arkenau at AACR Boston. Dive into the details and join us in advancing cancer research!💡ellipses.life/wp-content/upl… #AACR2023 #CancerInnovation 🚀

EP0031, our next-gen RET inhibitor, receives FDA Orphan Drug Designation. A crucial step in advancing cancer treatments. #OrphanDrug #EP0031 #EllipsesPharma ellipses.life/ellipses-ep003…

AS SEEN ON TV: Learn about our role in advancing Precision Medicine and how we validate promising assets through our Scientific Advisory Group. Check out the interview: ellipses.life/ellipses-pharm… #PrecisionMedicine #EllipsesPharma

Explore the cutting-edge of lung cancer treatment with Tobias Arkenau. Learn about the latest breakthroughs in clinical trials and the growing demand for next-generation therapies. Read more: pharmafocus.com/collections/ma… #LungCancer #PrecisionMedicine #Innovation #EllipsesPharma